美畅股份 reported revenue of ¥1.16B for the period ended 2026-06-30, +15.3% year on year. Net income was ¥0.31B, a 26.6% net margin on a 35.4% gross margin. Free cash flow for the period was ¥0.37B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.16B | +15.3% |
| Gross profit | ¥0.41B | — |
| Operating income | ¥0.35B | — |
| Net income | ¥0.31B | +265.7% |
| Gross margin | 35.4% | Net margin 26.6% |
| Revenue Q/Q | -3.5% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.75B | 64.6% |
| R&D | ¥0.02B | 1.8% |
| SG&A | ¥0.04B | 3.8% |
| Tax & other | ¥0.04B | 3.6% |
| Item | Amount |
|---|---|
| Total assets | ¥7.30B |
| Total liabilities | ¥0.70B |
| Shareholders' equity | ¥6.60B |
| Equity / assets | 90.4% |
| Operating cash flow | ¥0.37B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.37B |
| Cash conversion (OCF / net income) | 90% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
蓝盾光电 ・ 卡倍亿 ・ 南大环境 ・ 大宏立 ・ 圣元环保 ・ 杰美特 ・ 康泰医学 ・ 欧陆通 ・ 回盛生物 ・ 天阳科技 ・ 海晨股份 ・ 捷强装备
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies